Parkinson’s cell therapy developer files to go public
Aspen Neuroscience is looking to join the Nasdaq and raise more money to support its lead program, which aims to turn a patient's own cells into dopamine-producing neurons.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.